Neurocrine Lays Off Sales Force

Drug Industry Daily
KEYWORDS FDA / Markets
A A

Troubles continue for Neurocrine Biosciences in the wake of a regulatory delay of the insomnia drug indiplon as the company announced it is eliminating its sales staff.

To View This Article:

Login

Subscribe To Drug Industry Daily